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Abstract
Purpose Amyloid-beta (Aβ) peptides are involved in the in-
flammatory pathology of atherosclerosis. 18F-Florbetaben is a
PET tracer for clinical imaging of cerebral Aβ plaques in
Alzheimer’s disease (AD). We sought to determine whether
specific uptake of 18F-florbetaben in the carotid arteries can be
identified using a fully integrated hybrid PET/MRI system
and whether this uptake is associated with clinical cardiovas-
cular disease (CVD) risk factors.
Methods Carotid 18F-florbetaben uptake was quantified as the
mean of the maximum target-to-background ratio
(meanTBRmax) in 40 cognitively impaired subjects (age 68.2
± 9.5 years) undergoing 18F-florbetaben PET/MRI to diagnose
AD. Associations between carotid 18F-florbetaben uptake and
several CVD risk factors were assessed by univariate analysis
followed by a multivariate linear regression analysis.
Furthermore, carotid 18F-florbetaben uptake was compared
between patients with and without a positive cerebral Aβ
PET scan.
Results 18F-Florbetaben uptake was clearly visualized in the
carotid arteries. Values of meanTBRmax corrected for the blood
pool activity of the tracer showed specific 18F-florbetaben
uptake in the carotid wall. Male gender was associated with
carotid 18F-florbetaben uptake in the univariate analysis, and
was found to be an independent predictor of 18F-florbetaben
uptake in the multivariate regression analysis (standardized
regression coefficient β = 0.407, p = 0.009). Carotid 18F-
florbetaben meanTBRmax in patients with a positive cerebral
Aβ scan did not differ from that in patients without cerebral
Aβ deposits.
Conclusion Specific 18F-florbetaben uptake in human carotid
arteries was detected. Male gender was identified as an inde-
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pendent clinical risk factor. Therefore, 18F-florbetaben PET/
MRI might provide new insights into the pathophysiological
process in atherosclerosis.
Keywords PET . Amyloid-β . Florbetaben .
Atherosclerosis . Carotid arteries
Introduction
The development of atherosclerotic plaques is characterized
by accumulation of lipids, inflammatory cells and connective
tissue within the arterial wall [1–3]. Even though atheroscle-
rosis is usually a chronic, progressive process, abrupt rupture
of an atherosclerotic – so-called vulnerable – plaque can be-
come acutely life threatening by releasing embolic material
that leads to myocardial infarction or stroke. So far, no bio-
marker or imaging technique is able to assess and predict the
individual risk of plaque rupture and a subsequent acute car-
diovascular event beforehand.Whether and how a plaque rup-
tures is determined by its macroscopic structure and its micro-
scopic composition [4]. Arterial wall inflammation plays a
key role in atherosclerotic plaque rupture [2]. Obviously, spe-
cific detection of markers of arterial inflammation within a
vulnerable plaque through imaging represents a highly attrac-
tive approach to identifying patients at risk of rupture of such
an atherosclerotic plaque [5].
Amyloid-beta (Aβ) deposition is considered one of the
initial events in the pathogenesis of Alzheimer’s disease
(AD). Furthermore, Aβ 1-42 peptides are involved in the
inflammatory pathology of this neurodegenerative disorder
[6, 7]. However, there is cumulative evidence that atheroscle-
rotic disease as well as AD share some key pathophysiological
elements and pathways that promote disease [6, 8, 9].
Irrespective of whether Aβ peptides are deposited in vessels
of the central nervous system or atherosclerotic plaques in the
periphery, they are likely to promote and perhaps synergize
chronic inflammatory processes, which culminate in the
degeneration, malfunction and vulnerability of arterial walls
or plaques, respectively [6]. Activated platelets and/or
vascular wall cells have been found to be the most likely
source of the Aβ pool in aortic atherosclerosis lesions [6].
Aβ activates a cascade of proinflammatory events in
endothelial cells and macrophages involving cytokine
secretion and oxidative stress that leads to vascular disease
[9–12]. In addition, it has recently been shown in blood
samples from 1,464 haemodynamically stable patients that
Aβ levels are significantly and independently associated with
progression of arterial stiffness as well as with the incidence of
subclinical atherosclerosis and coronary artery disease (CAD).
Furthermore, Aβ blood levels can be used to substantially
improve risk stratification for cardiovascular death in patients
with stable CAD. [8].
Florbetaben is an 18F-labelled stilbene derivative that was
developed as a PET tracer for routine clinical use to visualize
Aβ plaques in the brain of AD patients [13]. A recently pub-
lished multicentre phase 3 study revealed that 18F-florbetaben
PET has high sensitivity and specificity for the detection of
histopathologically confirmed neuritic Aβ plaques [14].
Using a fully integrated hybrid PET/MRI system, we eval-
uated whether specific 18F-florbetaben uptake in the carotid
arteries can be identified and, subsequently, whether the ca-




This was a cross-sectional study of patients with suspected
AD admitted to the Department of Nuclear Medicine,
University of Leipzig, Germany, for further diagnostic evalu-
ation with clinically indicated 18F-florbetaben PET/MRI.
Scans were performed from May 2013 until August 2015
and were analysed for carotid 18F-florbetaben uptake. The
analysis was approved by the institutional Ethics Committee
and was performed according to the STROBE guidelines for
cohort, case-control, and cross-sectional studies [15]. All sub-
jects provided written informed consent for the PET/MRI
examination.
Questionnaire, biometric and biochemical measurements
The presence of CVD risk factors was prospectively assessed
based on the results of a questionnaire retrieved from patients’
records. The presence of hypertensionwas defined as a history
of systolic blood pressure >140 mmHg, or a diastolic blood
pressure >90 mmHg. Diabetes was defined as documented
diagnosis of type 1 or type 2 diabetic disease and the use of
an antidiabetic treatment (diet, oral medication, insulin treat-
ment). The definition of history of stroke included stroke and
transitory ischaemic attack. Weight and height were measured
and body mass index (BMI) calculated.
18F-Florbetaben PET/MRI
Simultaneous head/neck amyloid imaging with 18F-
florbetaben was carried out on a fully integrated PET/
MRI system (Biograph mMR; Siemens Healthcare,
Erlangen, Germany). The PET data were acquired from
90 to 110 min after intravenous injection of 297.7 ±
9.37 MBq of the tracer. These data were reconstructed
into a 256 × 256 matrix (voxel size 2.32 × 2.32 ×
2.03 mm) using the built-in 3D ordered subsets expecta-
tion maximization algorithm with eight iterations, 21
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subsets and a 3-mm gaussian filter. Standard corrections
for decay, scatter, dead time and attenuation were per-
formed. For attenuation correction, a two-point MRI
Dixon VIBE sequence (TR 3.6 ms, TE 1.23 ms, slice
thickness 3.12 mm, matrix 256 × 256, FOV 500 ×
300 mm) was acquired at 3 T in parallel with the PET
acquisition, resulting in segmented (air, soft tissue, fat)
attenuation coefficient maps. Amongst other MR se-
quences, anatomical data via a 3D T1 magnetization-
prepared rapid acquisition gradient echo (MPRAGE) se-
quence (TR 1,900 ms, TE 2.53 ms, slice thickness 1 mm,
matrix 256 × 256, FOV 250 mm) were obtained in parallel
with the PET acquisition.
Image analysis
Images were analysed on a dedicated commercially available
workstation (syngo.via VA30; mMR General Workflow;
Siemens Healthcare). An experienced reader (J.B.) analysed all
scans. The methodology for analysis and reproducibility of the
vascular PET measurements has previously been reported [16].
Briefly, arterial 18F-florbetaben uptake was quantified by manu-
ally drawing an individual region of interest (ROI) around the left
and right common carotid arteries on every slice of the T1-
weighted MPRAGE scan. The ROIs were then used to acquire
functional data from natively coregistered PET datasets. Next,










and advanced human carotid
plaques. a, b Aβ
immunoreactivity (brown) in an
AD-positive brain section
(positive control tissue). The inset
box in a is shown inmore detail as
the full image b. c–h Aβ
immunoreactivity (brown) in
carotid arteries from the 40
patients evaluated. The images
show intimal thickening in an
early plaque (c, e, g) and a thick
fibrous cap atheroma in an
advanced plaque (d, f, h). The
inset boxes E and F and the same
areas in more detail (full images e
and f) show the plaque, and the
inset boxes G and H and the same
areas in more detail (full images g
and h) show the adventitia
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(SUVmeanand SUVmax; mean and highest pixel activity within
the ROI) from PET were determined. Averaging the mean and
maximumSUVvalues of all arterial slices of both carotid arteries
led to meanSUVmean and meanSUVmax values.
The mean and maximal carotid artery target-to-background
ratios (TBRmean and TBRmax) were calculated by normalizing
the carotid artery SUVmeanand SUVmax to the mean SUVmean
of the blood pool measured in both jugular veins (JV). Thus,
the carotid artery TBR is a reflection of the specific carotid
artery wall 18F-florbetaben uptake. For measuring the JV
SUVs, ROIs of 3–4 mm diameter were placed on consecutive
slices bilaterally, and the results were averaged. TBRmean and
TBRmax were also averaged to obtain mean TBRmean




A total of 40 atherosclerotic carotid arteries (38 patients, mean
age 72 years, 64% men) were obtained at autopsy for the
analysis of Aβ protein expression by immunohistochemistry
in paraffin-embedded sections with intimal thickening, path-
ological thickening, a thick fibrous cap atheroma or
intraplaque hemorrhage. All plaques evaluated were classified
according to the method described by Virmani et al. [17] on
slides stained with haematoxylin and eosin. Material was col-
lected in agreement with the Dutch code of conduct for re-
sponsible use of human tissue (https://www.federa.org/code-
goed-gebruik). All patient data has previously been reported
[18]. For antigen retrieval, carotid artery sections and a AD-
positive human brain section (positive control) were treated
with 10 mM Tris/1 mM EDTA (pH 9) and then incubated
overnight at room temperature with mouse anti-Aβ (DAKO
M0172, diluted 1:50). Specific antigen–antibody binding was
visualized by incubation with horseradish peroxidase-labelled
goat anti-mouse secondary antibody (Brightvision) and
diaminobenzidine.
Statistical analysis
Continuous variables are expressed as means ± standard
deviation and categorical data as absolute numbers and
percentages. The normality of the data distributions was
tested using the Kolmogorov-Smirnov test and differences
were then evaluated using the t test for independent sam-
ples. Univariate analyses followed by a multivariate linear
regression analysis with backward elimination were used
to assess the associations between cardiovascular risk fac-
tors and carotid 18F-florbetaben uptake (meanTBRmax) [19,
20]. 18F-florbetaben meanTBRmax was treated as the re-
sponse (dependent) variable and cardiovascular risk fac-
tors as the explanatory (independent) variables for the
regression analysis. The explanatory variables included
were male gender, age >65 years, BMI, diabetes, hyper-
tension, history of stroke, and history of CAD. Following
this, the ENTER regression was used to determine inde-
pendent predictors of the response variables. All explan-
atory variables in the backward elimination model found
to be significantly associated with the 18F-florbetaben up-
take value were retained and entered into the regression
model as a block in a single step. This entry method was
preferred over the forward selection of variables since
Table 1 Characteristics of the 40 included patients and their 18F-
florbetaben PET/MRI data
Characteristic Value
Age (years), mean ± SD 68.2 ± 9.5




Body mass index (kg/m2)
Mean ± SD 25.8 ± 3.13
<25, n (%) 15 (37.5)
≥25 to <30, n (%) 21 (52.5)
≥30, n (%) 4 (10)
Medical history, n (%)
Hypertensiona 27 (73.0)
Diabetesb 7 (18.4)
Type I 2 (28.6)
Type II 5 (71.4)
History of stroke, n (%)c 2 (5.9)
History of coronary artery disease, n (%)d 5 (17.9)
Blood pool activitye 0.95 ± 0.22
Carotid uptake valuesf
meanSUVmean 1.07 ± 0.2
meanSUVmax 1.65 ± 0.34
Carotid TBR valuesg
meanTBRmean 1.15 ± 0.16
meanTBRmax 1.77 ± 0.38
Positive cerebral 18F-florbetaben PET/MRI, n (%) 21 (52.5)
SUV standardized uptake value, TBR target-to-background-ratio
a Three values missing
b Two values missing
c Twelve values missing
d Six values missing
e Average of the mean 18 F-florbetaben SUV values of all analysed slices
of the left and right jugular veins (meanSUVmean)
f By averaging the mean andmaximumSUV values of all arterial slices of
the left and right carotid artery, meanSUVmean and meanSUVmax value were
derived for the carotid arteries, respectively
g Carotid SUVmean and SUVmax values divided by the blood pool
meanSUVmean
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only a few significant variables were left for a relatively
low number of cases after excluding all the explanatory
variables without a significant association with the differ-
ent carotid wall 18F-florbetaben uptake values. The results
of the multiregression models are presented with the stan-
dardized regression coefficients (β), the 95% confidence
intervals, and the p values indicating the statistical signif-
icance of the estimates. All statistical analyses were per-
formed using SPSS version 16.0 (SPSS, Chicago, IL).
Results
Aβ immunohistochemistry in human atherosclerosis
Aβ deposition was present in human atherosclerotic plaques
(Fig. 1) as previously reported [21]. Aβ deposition was pre-
dominantly present in atherosclerotic plaques (Fig. 1e, f) and
adventitia (Fig. 1g, h), but was absent from the media. In
carotid arteries with intimal thickening only very few cells
were positive (Fig. 1c, e, g), while clear deposition, mostly
in macrophages, increasing with plaque progression to ad-
vanced atheromas (Fig. 1d, f, h).
Aβ imaging in human carotid arteries
The PET/MRI scans in 40 patients provided appropriate im-
aging quality and were therefore suitable for analysis. Table 1
shows the demographic characteristics and 18F-florbetaben
PET/MRI parameters of the study population. On average, 7
± 4 slices of the left common carotid artery and 6 ± 4 slices of
the right common carotid artery were analysed to derive the
18F-florbetaben uptake.
In seven patients, the anatomy of only one common carotid
artery (six left, one right) could be appropriately assessed.
However, in all of these patients, analysis of the respective
carotid artery provided sufficient data for inclusion in the
analysis. 18F-florbetaben uptake in the carotid arteries as well
as in the JV could be easily identified by visual inspection of
the PET/MRI overlay images in all patients (Fig. 2).
Furthermore, ROIs for semiquantitative analysis of 18F-
florbetaben uptake were precisely placed in all analysed
vessels.
The carotid meanSUVmean and meanSUVmax values were sig-
nificantly higher than the values of the venous blood pool
(1.07 ± 0.2 vs. 0.95 ± 0.22 and 1.65 ± 0.34 vs. 0.95 ± 0.22,
respectively; both p < 0.0001) leading to meanTBRmean and
meanTBRmax values >1 (Table 1). In 21 patients (52.5%),
Fig. 2 Focally increased 18F-florbetaben uptake in the left common
carotid artery. Top set of images Coronal and transverse T1-W MR
images, fused PET/MR images and PET-only images. Bottom pair of
images Transverse PET slice with a ROI (white circle) placed around
the lumen of the left common carotid artery including the focally
increased 18F-florbetaben uptake, and a PET maximum intensity
projection image with the carotid artery hot spot. Both visual and
semiquantitative analyses revealed higher tracer uptake in the left than
in the right common carotid artery (SUVmean left 1.33, right 1.06; SUVmax
left 1.83, right 1.22, ROI for the right common carotid artery not shown).
A standard ROI within the lumen of the left jugular vein was used (not
shown) for estimation of the 18F-florbetaben blood pool activity for
calculation of the target-to-background ratio
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positive cerebral 18F-florbetaben uptake was seen. There was
no significant difference in carotid 18F-florbetaben
meanTBRmax between these patients and patients with a normal
cerebral 18F-florbetaben scan (1.74 ± 0.44 vs. 1.81 ± 0.31, p =
0.536).
18F-Florbetaben and CVD risk factors
Table 2 shows the results of the univariate analysis of the
association between carotid 18F-florbetaben uptake expressed
as meanTBRmax and several well-known clinical CVD risk fac-
tors (male gender, age >65 years, BMI ≥30 kg/m2, diabetes,
hypertension, history of stroke, history of CAD). Only male
gender showed a significant association with the 18F-
florbetaben uptake in the carotid arteries (1.92 ± 0.39 vs.
1.61 ± 0.30 in female patients, p = 0.009; Table 2, Fig. 3a,
b). Multivariate linear regression analysis with backward
elimination with a model including all variables as mentioned
above was then performed to identify clinical CVD risk fac-
tors independently associated with carotid 18F-florbetaben up-
take (Table 3). Male gender (β = 0.393, p = 0.038) was the
only variable showing a significant association with the
meanTBRmax in the carotid arteries. This risk factor (with a p
value < 0.10) was exclusively retained in the model for the
ENTER regression (Table 3). The ENTER regression showed
that male gender was an independent positive predictor of 18F-
florbetaben uptake (β = 0.407, p = 0.009; Table 2).
Discussion
BClassical^ imaging modalities such as invasive angiography,
CT angiography and MRI do not provide sufficient informa-
tion on specific characteristics (e.g. vulnerability) of arterial
plaques. Identifying individual patients with vulnerable arte-
rial plaques carrying a high risk of rupture is therefore a central
challenge in cardiovascular medicine. Over the past decade
there has been an increasing interest in noninvasive functional
imaging of vascular inflammation and different parts of the
underlying complex pathological processes of atherosclerosis
by means of PET [22]. To our knowledge, amyloid tracers
have not so far been utilized in this context. We identified
PET imaging with the Aβ tracer 18F-florbetaben as a suitable
approach to specifically identifying patients with increased
carotid 18F-florbetaben uptake. The significantly higher arte-
rial 18F-florbetaben uptake compared with the venous blood
pool activity of the tracer clearly indicates specific arterial
tracer uptake, which consequently led to meanTBRmean and
meanTBRmax ratios of >1. A nonspecific arterial tracer uptake
would be expected to show a ratio of ≤1 [23]. Therefore, it is
likely that 18F-florbetaben PET is able to specifically image
Aβ peptides in the arterial wall and/or the atherosclerotic
Table 2 Univariate analysis of the associations between clinical
cardiovascular disease risk factors and carotid 18F-florbetaben uptake
expressed as meanTBRmax
Risk factor 95% confidence interval p value
Male gender 0.08–0.527 0.009
Age >65 years −0.412–0.09 0.202
Body mass index ≥30 kg/m2 −0.276–0.535 0.522
Diabetes −0.366–0.146 0.389
Hypertension −0.295–0.279 0.956
History of stroke −0.779–0.397 0.513
History of coronary artery disease −0.126–0.158 0.432
After confirming normality of the data distribution, univariate analysis
was performed using the t test for independent samples
Table 3 Multivariate linear regression analysis with backward elimination and ENTER analysis to identify clinical cardiovascular disease risk factors
associated with carotid 18F-florbetaben uptake expressed as meanTBRmax (the response variable)
Explanatory variable Standardized coefficient (β) 95% confidence interval Adjusted R2 Significance p value
0.122 0.038
Backward analysisa Male gender 0.393 0.014–0.477 0.038
0.144 0.009
ENTER analysisb Male gender 0.407 0.08–0.527 0.009
a Explanatory variables: male gender, BMI ≥30 kg/m2 , age >65 years, diabetes, hypertension, history of stroke, history of coronary artery disease.
Variables were retained in the model when p < 0.10 and then entered into the ENTER analysis
b Explanatory variable: male gender
Fig. 3 Relationships between cardiovascular disease risk factors and
carotid 18F-florbetaben uptake expressed as meanTBRmax. a Male gender
was a significant independent predictor of carotid 18F-florbetaben uptake
after correction for other risk factors (p = 0.009). Thus men showed
significantly higher carotid meanTBRmax values than women. b Factors
showing no statistically significant relationship with carotid 18F-
florbetaben uptake: age >65 years, BMI ≥30 kg/m2, hypertension,
diabetes, history of stroke, and history of coronary artery disease
(CAD). None of these cardiovascular risk factors was significantly
related to the 18F-florbetaben uptake in the carotid arteries in either the
univariate analysis or the multivariate linear regression analysis. The data
are presented as medians (bold lines), 25th and 75th percentiles (boxes),
and 5th and 95th percentiles (whiskers); circles represent outliers
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plaque even though histological confirmation of our imaging
results are lacking. Our results indicate that 18F-florbetaben is
able to image peripheral Aβ deposition in addition to the
originally considered detection of intracerebral deposits in
the clinic. In an approach comparable to ours, a similar PET
tracer to 18F-florbetaben which is also used for noninvasive
imaging of cerebral Aβ in AD, namely 11C-labelled
Pittsburgh B compound (11C-PiB), was recently successfully
used for noncerebral Aβ imaging in cardiac amyloidosis [24].
It is now considered that atherosclerosis and AD cerebro-
vascular amyloidosis share pathophysiological pathways, de-
spite their different end-stage manifestations [6]. Lee et al.
found that serum Aβ levels are elevated in stroke patients
and that both the infarct size and the initial National
Institutes of Health Stroke Scale (NIHSS) score are signifi-
cantly positively correlated with serum Aβ levels [25]. More
recently, the clinical relevance of Aβwith regard to CVD was
further shown in a study by Stamatelopoulos et al. who found
that Aβ blood levels in humans are independently associated
with the progression of arterial stiffness, incident subclinical
atherosclerosis, and incident coronary heart disease [9]. From
a pathophysiological point of view, Kokjohn et al. found that
atherosclerotic lesions contain a heterogeneous mixture of Aβ
peptides [6]. These Aβ peptides most likely originate in the
cells of the vascular walls that express Aβ precursor proteins/
protease nexin-2/Aβ and in platelets that take part in the ath-
erosclerotic inflammatory and disturbed coagulation cascades
[6, 21, 26]. Both processes are inherent to arterial wall degen-
eration as part of the atherosclerotic disease process. The pres-
ence of Aβ peptides in atherosclerotic plaques may synergis-
tically increase the chronic inflammatory processes that sus-
tain this degeneration and the destruction of the arterial walls.
This is because they mediate the process of increased and
persistent synthesis of proinflammatory molecules by activat-
ed macrophages and activated platelets. As a consequence,
focal vascular inflammatory response in the vulnerable
region of atheroma plaques may contribute to plaque in-
stability and rupture [27].
Although it appears that the general contributions of Aβ to
the inflammatory reactions in atherosclerosis and AD are es-
sentially the same [6, 13, 14], we did not observe higher ca-
rotid 18F-florbetaben uptake in patients with a positive cere-
bral Aβ scan than in those with a negative cerebral Aβ scan.
Our results indicate that, despite the most likely shared path-
ophysiological basis of atherosclerosis and AD with regard to
Aβ mediated inflammation, one cannot assume a completely
common character of this inflammatory reaction in the brain
and the non-cerebral arteries. This is in accordance with the
results of the previously published Baltimore Longitudinal
Study of Aging (BLSA), which showed that individuals with
coronary or aortic atherosclerosis per se are not at increased
risk of AD [28]. In contrast, intracranial atherosclerosis was
confirmed as a strong risk factor for dementia [29]. However,
our findings need to be confirmed in well-powered prospec-
tive trials.
Supporting the clinical relevance of our results, we
found that male gender, one of the well-known CVD risk
factors, was independently associated with 18F-
florbetaben uptake in the carotid arteries after adjustment
for other CVD risk factors. This is interesting as previous
studies with 18F-FDG PET have also indicated a signifi-
cant association between arterial 18F-FDG uptake, as a
marker of arterial wall and/or plaque inflammation, and
male gender [29–32]. Moreover, as revealed by our im-
munohistochemistry study, Aβ immunoreactivity was
mostly present in atherosclerotic plaque macrophages.
The fact that besides male gender none of the other eval-
uated CVD risk factors was found to be significantly re-
lated to carotid 18F-florbetaben uptake might be related to
the rather small population in this study, the missing
values for some of the collected cardiovascular risk fac-
tors and the fact that our patient population was not a
dedicated cardiovascular risk population. Thus, well-
powered, prospective studies need to be performed next
to provide more conclusive results with regard to the as-
sociation between arterial 18F-florbetaben uptake and clin-
ical CVD risk factors.
Due to the study design involving the inclusion of patients
with suspicion of AD, we were not able to confirm our imag-
ing results by histology in these patients. Therefore, future
studies need to histologically confirm the correlation between
vascular 18F-florbetaben uptake and the presence of arterial
Aβ deposition, in for example imaging of carotid artery ste-
nosis. However, immunohistochemistry in a separate cohort
representing different stages of atherosclerosis supported pref-
erential uptake in advanced atherosclerotic plaques, while ar-
teries with intimal thickening were mostly negative.
Furthermore, in the absence of a dedicated vascular MR se-
quence in the retrospective setting of the study, we were not
able to correlate the PET signal to a particular carotid plaque
which might have been seen on the MRI scan. Another limi-
tation was the rather small study population that potentially
impaired the correlation between carotid 18F-florbetaben up-
take and clinical CVD risk factors or distinct cardiovascular
biomarkers as well as the correlation with the cerebral Aβ
deposition. These issues will have to be addressed in future
trials with dedicated CVD profiling.
Conclusion
PET can visualize specific 18F-florbetaben uptake in human
carotid arteries for which male gender was identified as an
independent clinical risk factor. Therefore, we consider 18F-
florbetaben PET/MRI as valuable for the noninvasive imaging
of arterial Aβ deposition, providing new insights into the
pathophysiological process of atherosclerosis.
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